Table 2.
Outcome | Exposure group | N | Number of events | Follow-up time* (years) | Incidence rate (per 100 person-years) | Model | Hazard ratio (95% CI) | |
---|---|---|---|---|---|---|---|---|
| ||||||||
Mean ± SD | Median | |||||||
All-cause mortality | Did not receive heparin post-GIB | 184 | 28 | 0.25±0.36 | 0.05 | 61.7 | ||
| ||||||||
Received heparin post-GIB | 1158 | 392 | 0.56±0.39 | 0.56 | 60.5 | Unadjusted | 1.01 (0.69–1.48) | |
Model 1 | 0.94 (0.64–1.40) | |||||||
Model 2 | 0.91 (0.61–1.37) | |||||||
| ||||||||
Recurrent GIB | Did not receive heparin post-GIB | 184 | 9 | 0.23±0.35 | 0.04 | 21.4 | ||
| ||||||||
Received heparin post-GIB | 1158 | 81 | 0.54±0.40 | 0.49 | 13.0 | Unadjusted | 0.78 (0.39–1.57) | |
Model 1 | 0.66 (0.33–1.34) |
SD=standard deviation CI=confidence interval
Model 1: adjusted for all variables that were significantly different between the groups in univariate analysis at the p<0.20 level (age, race, cancer, deep vein thrombosis, pulmonary embolism, transfusions received during hospitalization, days from hospital admission for GIB to resumption of outpatient HD, Kt/V, reuse of dialysis filter.)
Model 2: Model 1 + all demographics (age, sex, race, ethnicity, years on dialysis), all comorbidities (arrhythmia, cancer, coronary artery disease, deep vein thrombosis, diabetes mellitus, previous gastrointestinal bleeding, heart failure, hemorrhagic stroke, ischemic stroke, liver disease, peripheral vascular disease, pulmonary disease, pulmonary embolism), hemoglobin concentration, platelet count, and access type.